Skip to product information
1 of 1

Cellarom hPL-EliteGro-Adv GMP Gamma Irradiated

Cellarom hPL-EliteGro-Adv GMP Gamma Irradiated

Cellarom Store

Request for Quote

Discover our premium xeno-free Human Platelet Lysate (hPL) solutions for cell culture expansion.

  • Superior growth factor concentrations

  • Eliminates animal-derived components

  • Reduces contamination risks

  • Ensures regulatory compliance for clinical applications

  • EliteGro™-Adv. is animal serum-free and xenogeneic-free

  • Ideal for research or commercial development of cell therapies

  • Supports proliferation of various mesenchymal stem cells

  • No alteration in cell morphology or characterization

  • Manufactured in cGMP-compliant facility

  • Gamma irradiated for safety

  • Available in 50 mL and 500 mL bottles

Application

Supports the expansion of hMSCs and growth of human endoehelial cells and fibroblasts. Effective substitute for fetal bovine serum (FBS). No Heparin needed

Cell Type

hMSCs

Storage

- 20C

Specification

  • 50ml bottle
  • GMP
  • Gamma Irradiated
  • Doesn't require addition of heparin and does not contain any anticoagulant
  • US FDA MF (biologics Master File)
  • US FDA Reviewed for IND Approval
View full details

Request for Quote

Contact us for quote and additional information

Scale up from pilot to clinical trials and commercialization with expert guidance on media selection, regulatory compliance, and supply chain optimization from North America's cell culture specialists.

Empowering Cell Therapy Organizations to Innovate

Cellarom was born from a desire to bridge the gap between research and development, pilot production and commercialization. We recognized the challenge of balancing scientifically acceptable product performance with the need to reduce manufacturing costs to produce cost-effective therapies.

At Cellarom, we are dedicated to:

  • Bridging Product Development and Commercialization in Cell Therapy
  • Cost-Effective and High-Quality Cell Therapy raw materials and solutions
  • Capability for Scaling Up Cell Therapy Production